Terminated PHASE1 INTERVENTIONAL 1-arm NCT00003147

Gene Therapy in Treating Patients With Cancer of The Liver

Phase I Study of Percutaneous Injections of Adeno-Virus p53 Construct (ADENO-p53) for Hepatocellular Carcinoma

Sponsor: National Cancer Institute (NCI)

Updated 7 times since 2017 Last updated: Feb 4, 2013 Started: Feb 28, 1998 Primary completion: Jun 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Administratively complete.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Liver Cancer trials with similar outcome

Browse all Liver Cancer trials

This PHASE1 trial investigates Liver Cancer and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Feb 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States
• The Bronx, United States